 Home > Biochemistry News > Biotechnology News > Combining the advantages of CAR and TCR solid tumor innovative cell therapy into the clinic

Combining the advantages of CAR and TCR solid tumor innovative cell therapy into the clinic

 Last Update: 2021-09-30
 Source: Internet
 Author: User

Tags

protein type aa

therapy

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, Triumvira Immunologics announced that its TAC-T cell therapy TAC01-HER2 clinical trial has completed the first patient administration for the treatment of human epidermal growth factor receptor 2 (HER2) positive solid tumors

TAC is a hybrid molecule composed of multiple protein domains.

The advantage of this design is that the self-regulation mechanism of the TCR receptor is retained, so that TAC-T cells will not be activated all the time

▲The difference between TAC and CAR (Image source: Triumvira's official website)

Compared with TCR-T cells, the combination of TAC and antigen does not need to rely on the major histocompatibility complex (MHC) to present the antigen, so it has flexibility in the type of target antigen

This clinical trial aims to evaluate the safety, tolerability and effectiveness of TAC01-HER2 in patients with HER2-positive metastatic, advanced, or unresectable solid tumors, and plans to recruit approximately 70 subjects

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express combines the advantages of CAR and TCR, and innovative cell therapy for solid tumors enters the clinic

09-30

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Combining the advantages of CAR and TCR solid tumor innovative cell therapy into the clinic

Related Articles

Express combines the advantages of CAR and TCR, and innovative cell therapy for solid tumors enters the clinic